» Authors » Marina V Shestakova

Marina V Shestakova

Explore the profile of Marina V Shestakova including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 54
Citations 701
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Minniakhmetov I, Khusainova R, Laptev D, Yalaev B, Karpova Y, Deev R, et al.
Int J Mol Sci . 2025 Jan; 26(2). PMID: 39859454
Analyzing the genetic architecture of hereditary forms of diabetes in different populations is a critical step toward optimizing diagnostic and preventive algorithms. This requires consideration of regional and population-specific characteristics,...
2.
Lokhov P, Balashova E, Trifonova O, Maslov D, Shestakova E, Shestakova M, et al.
Metabolites . 2024 Mar; 14(3). PMID: 38535328
The clinical blood metabogram (CBM) was developed to match a tailored analysis of the blood metabolome to the time, cost, and reproducibility constraints of clinical laboratory testing. By analyzing the...
3.
Khapchaev A, Vorotnikov A, Antonova O, Samsonov M, Shestakova E, Sklyanik I, et al.
Biomedicines . 2024 Feb; 12(2). PMID: 38397940
Saturated free fatty acids are thought to play a critical role in metabolic disorders associated with obesity, insulin resistance, type 2 diabetes (T2D), and their vascular complications via effects on...
4.
Makhnovskii P, Lednev E, Gavrilova A, Kurochkina N, Vepkhvadze T, Shestakova M, et al.
Physiol Genomics . 2023 Aug; 55(10):468-477. PMID: 37545425
Obesity- and type 2 diabetes mellitus-induced changes in the expression of protein-coding genes in human skeletal muscle were extensively examined at baseline (after an overnight fast). We aimed to compare...
5.
Dmitriev I, Severina A, Zhuravel N, Yevloyeva M, Salimkhanov R, Shchelykalina S, et al.
Diagnostics (Basel) . 2023 May; 13(9). PMID: 37174997
Simultaneous pancreas-kidney transplantation (SPKT) can improve long-term patient survival and restore endogenous insulin secretion in recipients with type 1 diabetes (T1D). There are currently few data on glucose fluctuations assessed...
6.
Bongaerts B, Kuss O, Bonnet F, Chen H, Cooper A, Fenici P, et al.
Diabetes Obes Metab . 2023 Mar; 25(7):1890-1899. PMID: 36906837
Aim: To identify distinct HbA1c trajectories in people with type 2 diabetes (T2D) starting second-line glucose-lowering therapy. Materials And Methods: DISCOVER was a 3-year observational study of individuals with T2D...
7.
Charbonnel B, Chen H, Cid-Ruzafa J, Cooper A, Fenici P, Gomes M, et al.
Diabetes Obes Metab . 2022 Sep; 25(1):46-55. PMID: 36111434
Aims: To describe glucose-lowering treatment regimens and glycated haemoglobin (HbA1c) trajectories in individuals with type 2 diabetes (T2D) over 36 months of follow-up from the start of second-line therapy. Materials...
8.
Malik A, Chen H, Tang F, Chan P, Cooper A, Gomes M, et al.
Indian Heart J . 2022 Aug; 74(5):398-405. PMID: 35926587
Background: We sought to describe global patterns in achievement of risk factor control for primary prevention in patients with T2D and explore the association of country's GNI/capita with risk factor...
9.
Hejjaji V, Gorgojo-Martinez J, Tang F, Garnelo J, Cooper A, Medina J, et al.
Diabetes Obes Metab . 2022 May; 24(9):1734-1740. PMID: 35546275
Aims: To estimate real-world change in weight over 3 years and the factors influencing it in participants who are overweight and live with type 2 diabetes. Materials And Methods: DISCOVER...
10.
Gomes M, Tang F, Chen H, Cid-Ruzafa J, Fenici P, Khunti K, et al.
Front Endocrinol (Lausanne) . 2022 May; 13:831676. PMID: 35527995
DISCOVER is a 3-year observational study program of 15,983 people with type 2 diabetes initiating second-line glucose-lowering therapy in 38 countries. We investigated the association between socioeconomic status and both...